Alligator Bioscience AB (publ) Interim report January-March 2020
Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...
Alligator Bioscience’s Board of Directors reduces its fees and offers possibility for postal voting in front of the Annual General Meeting
Lund, Sweden, April 20, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company's Nomination Committee, ...
Alligator Bioscience increases focus on clinical development
Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...
Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic
Lund, Sweden, 1 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new pati ...
Notice of annual general meeting in Alligator Bioscience AB (publ)
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience appoints Andreas Johannesson as interim Chief Financial Officer
Lund, Sweden, 5 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed inte ...
Alligator Bioscience’s Annual Report 2019 published
Lund, Sweden, 2 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutica ...
Alligator Bioscience AB Year-end Report January-December 2019
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...
Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer
Lund, Sweden, December 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successful ...